Factor XI Levels in Acute Ischemic Stroke

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

450 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-05-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the utility of measuring coagulation factor activities in the setting of acute ischemic stroke, as potential markers of inherited thrombotic risk. The investigators will determine if relationships exist between coagulation factors, including factor VIII, factor IX, and factor XI and clinical diagnosis, classification, and outcome. The investigators will determine if any significant elevations of these factor activities are independent thrombotic risk factors.

Null Hypothesis: There is no statistical difference between coagulation factors, including factors VIII, IX, or XI activity levels in patients having acute ischemic stroke as compared to acute stroke mimics.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months

NCT06841978

Stroke Acute Ischemic Stroke

NOT_YET_RECRUITING PHASE3

Thrombolysis in Factor Xa-inhibitors Trial

NCT06878066

Stroke Stroke (in Patients With Atrial Fibrillation) Ischemic Stroke +6 more

RECRUITING PHASE3

Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic

NCT05415150

Acute Ischemic Stroke

UNKNOWN PHASE1/PHASE2

Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke

NCT04818944

Acute Ischemic Stroke Ischemic Stroke

WITHDRAWN PHASE1/PHASE2

Biomarkers of Acute Stroke in Clinic

NCT03897478

Ischemic Stroke Ischemia Atrial Fibrillation +14 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Increased factor XI levels have been associated with venous thromboembolic disease and acute myocardial infarction. However, checking factor XI levels is not currently indicated to assess individual thromboembolic risk. Factor XI is an important protease that links the extrinsic arm of the coagulation cascade with the intrinsic arm through dual activation by both factor XII and thrombin. Since thrombin is a downstream product of factor XI, a feedback loop is created that amplifies thrombin production and ultimately results formation of a stable fibrin clot. Sufficient thrombin generation via this pathway also contributes to activation of the Thrombin-Activatable Fibrinolysis Inhibitor (TAFI). Activated TAFI downregulates fibrinolysis and has been implicated as part of the association between elevated factor XI levels and venous thromboembolic disease. One study found that functional TAFI levels of \> 120% increased the risk of ischemic stroke approximately 6-fold, however, the association between Factor XI and ischemic stroke has yet to be firmly established. We recently performed a preliminary retrospective analysis of 78 patients with stroke or transient ischemic attack (TIA) and found that patients with factor XI activity levels above the 95th percentile of an age and sex matched reference population had a relative risk of 5.3 for stroke or TIA. Factor XI measurements may be able to help identify thromboembolic disease, aiding in the determination of stroke etiology.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Factors VIII, IX and XI levels measured

Case group

No interventions assigned to this group

Non Stroke patients

This is the control group. This group represents patients who were initially evaluated for stroke.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Those clinically diagnosed with acute ischemic stroke
* 18 years of age or greater

Exclusion Criteria

* Those without clinical diagnosis of acute ischemic stroke will be included in the control group.
* Patients with hemorrhagic strokes
* Inpatients who are evaluated through the Brain Attack protocol

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No